Combining onabotulinumtoxina and CGRP monoclonal antibodies in chronic migraine: A systematic review

Key Points

• Combining onabotulinumtoxina and CGRP monoclonal antibodies shows improved outcomes in chronic migraine treatment.
• Meta-analysis of various studies reveals significant reductions in headache frequency when using both therapies together.
• Observational analysis of treatment effects highlights efficacy in patients unresponsive to standard treatments.
• Results suggest further investigation into this dual therapy is warranted for chronic migraine management.